Back to Natixis Natixis

KYMR

12 quarters

Position history for NatixisNatixis's holdings in Kymera Therapeutics, Inc.

No. Natixis exited its KYMR (Kymera Therapeutics) position in Q3 2025. Its Q2 2025 13F listed 2,595 shares worth $113,246. Natixis first reported KYMR in Q2 2021 and held it in 9 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$318,000

Total Shares Change

-6,564

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q3
Latest
Exited
0
-100.0%
$00.0%$56.60
0
2025-Q2
Decreased
2,595
-79.5%
$113,2460.0%$43.64
0
2025-Q1
New
12,674
-
$355,7590.0%$27.37
33
2024-Q2
Exited
0
-100.0%
$00.0%$29.85
0
2024-Q1
Decreased
1,979
-50.2%
$79,5560.0%$40.20
0
2023-Q4
Decreased
3,971
-5.0%
$101,1020.0%$25.46
0
2023-Q3
New
4,180
-
$58,1020.0%$13.90
29
2022-Q2
Exited
0
-100.0%
$00.0%$19.69
0
2022-Q1
Decreased
8,803
-48.7%
$373,0000.0%$42.32
0
2021-Q4
Decreased
17,148
-69.5%
$1.1M0.0%$63.49
0
2021-Q3
Increased
56,139
+755.3%
$3.3M0.0%$58.74
43
2021-Q2
New
6,564
-
$318,0000.0%$48.50
33

Other major holders of KYMR: FMR LLC, Baker Bros. Advisors LP, Avoro Capital Advisors LLC, T. Rowe Price Associates, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used